Smith+Nephew’s TESSA System Gains FDA Nod, Setting New Standard for AI-Powered Orthopedic Surgery
Event summary
- Smith+Nephew’s TESSA Spatial Surgery System received FDA De Novo classification on July 29, 2026.
- The system uses AI and augmented reality to enhance precision in ACL reconstruction surgery.
- First indication is femoral anterior cruciate ligament (ACL) reconstruction, addressing common causes of surgical failure.
- Commercial launch begins in Q3 2026, with broader deployment expected in 2027.
The big picture
Smith+Nephew’s FDA approval for the TESSA Spatial Surgery System marks a significant step in integrating AI and augmented reality into orthopedic surgery. The technology addresses critical challenges in ACL reconstruction, positioning Smith+Nephew as a leader in personalized, data-driven surgical solutions. This development aligns with broader industry trends toward digital transformation in healthcare, where precision and efficiency are increasingly driven by advanced computing and AI.
What we're watching
- Market Adoption
- The pace at which surgeons and hospitals adopt the TESSA System will determine its revenue impact.
- Regulatory Leadership
- Whether Smith+Nephew can leverage this FDA classification to set industry standards for future spatial surgery devices.
- Technological Expansion
- How quickly the TESSA System’s capabilities expand beyond ACL reconstruction into other arthroscopic procedures.